Unternehmensübersicht
BioVie Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of therapeutic interventions for neurological, neurodegenerative disorders, and advanced liver disease within the United States market. The company functions within the broader Healthcare sector, specifically targeting the specialized Biotechnology industry, which focuses on the discovery and development of innovative biological products rather than large-scale commercial manufacturing. With a market capitalization of $11.24M and an employee count of 13, the organization maintains a very small-scale operational footprint typical of early-stage clinical development firms. The minimal revenue reported in the trailing twelve months (N/A) combined with this low employee count indicates that the company's current valuation is driven primarily by its intellectual property pipeline and potential future commercialization prospects rather than established cash-flowing operations.
Finanzielle Gesundheit
The financial performance metrics reveal a significant cash burn, with Net Income (TTM) standing at $-17,478,136 and EBITDA recorded at $-17,968,812, while the Revenue (TTM) figure is listed as N/A. The substantial negative gap between the reported net income and the EBITDA figure highlights a cost structure burdened by significant non-operating expenses or interest costs that are not fully offset by current operational earnings. The company's Free Cash Flow stands at $-8,277,755, indicating a continuous consumption of cash reserves to fund research and development activities, which limits immediate financial flexibility but is a common characteristic of clinical-stage entities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, reflecting the fact that the company has not yet generated sufficient revenue to calculate meaningful profitability ratios or that revenues are negligible relative to expenses. In terms of leverage, the company holds $20.54M in cash against $314,915 in debt, resulting in a Debt to Equity ratio of 1.64, which suggests a capital structure heavily reliant on equity financing or where the debt figure is small relative to the massive cash hoard. The Current Ratio of 7.25 demonstrates robust short-term liquidity, implying the company possesses ample current assets to cover its current liabilities without immediate risk of insolvency. However, the Return on Equity of -80.7% and Return on Assets of -47.2% indicate that management is currently destroying shareholder value, a standard metric for loss-making companies but one that signals a lack of immediate effectiveness in generating returns on the capital deployed.
Bewertungsanalyse
Valuation multiples for BioVie Inc. are mixed due to the lack of profitability, with the P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.34, which implies that the market is pricing in potential future earnings recovery or that the stock is currently trading at a loss relative to forward expectations. The Price to Book ratio stands at 0.58, indicating that the market values the company at less than its net asset value, suggesting that the stock is trading at a discount to the underlying book value of its assets. The Price to Sales ratio is N/A due to the absence of reported revenue, while the EV/EBITDA metric is 0.50, a figure that, while low for a public company, reflects the negative earnings base and suggests a valuation anchored heavily in asset backing rather than earnings multiples. The stock has exhibited significant volatility over the past year, with a 52-Week High of $13.20 and a 52-Week Low of $1.06, meaning the current trading environment is highly dependent on clinical trial milestones and capital market sentiment. The Beta value of 0.56 indicates that the stock's price volatility is significantly lower than the broader market, suggesting that the stock moves less sharply than the S&P 500 in response to general market fluctuations.
Growth & Income
Growth metrics for BioVie Inc. are currently unavailable, with Revenue Growth (YoY) and Earnings Growth (YoY) both listed as N/A, which precludes any quantitative comparison between the speed of revenue expansion and earnings generation. As the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, meaning the company retains all its limited earnings and cash flow to reinvest into its drug development pipeline rather than distributing income to shareholders. The absence of a dividend payout strategy aligns with the company's stage of development, where capital preservation and funding for Phase 2 trials for BIV201 are prioritized over income generation for investors. Consequently, the overall growth and income profile is characterized by total reliance on capital appreciation potential and the successful progression of its clinical assets rather than current income yields or historical growth rates.